Evotec’s strategic alliance with Celgene Corp. has been expanded to include a new cell type, triggering $9.0 million payment to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Since then, the companies have achieved several milestones including advancement of one program into lead optimization as well as including additional cell lines and now a new cell type. Currently approve...